Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and Research Institute, shared Annals of Oncology’s post on LinkedIn, adding:
“ADCs continue to make their mark in head and neck oncology.
Becotatug Vedotin (anti-EGFR ADC) in heavily pretreated recurrent/metastatic NPC after chemotherapy plus PD-1/PD-L1 failure:
- n=173 randomized
- ORR: 30.2% vs 11.5% (chemo)
- PFS: 5.82 vs 2.83 months (HR 0.63)
- OS: 17.1 vs 12.0 months (HR 0.73, immature)
A meaningful signal in a population with few effective options. The ADC era in H&N cancer is accelerating.”
Quoting Annals of Oncology’s post:
“Article in press: Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial.”
Title: Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized Trial
Authors: F. Han, Y.Q. Xiang, X.H. Wang, S. Qu, L.Q. Tang, X.L. Shu, P. Zhang, S.F. Qiu, Y.J. Zhou, Y. Guo, G.Q. Xu, Q. Li, K.Y. Yang, Y.Q. Du, M.J. Xu, J.G. Li, F. Wang, S.T. Huang, Y.J. Huang, H. Wu, X.Z. Chen, Y. Wei, W.L. Wu, S.M. Pan, H.M. Lin, S.W. Xiao, Y.W. Dou, R. Dai, P. Zhang, Y.S. Jin, R.H. Xu
Other articles featuring Cesar Perez and Annals of Oncology on OncoDaily.
